[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635321":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":68,"collaborators":26,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":26,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":26,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Chengdu Suncadia Medicine Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HRS-5765 group","EXPERIMENTAL","Participants will be assigned to one of the planned dose cohorts and receive specified dose of HRS-5765.",[13],"Drug: HRS-5765 Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"HRS-5765 placebo group","PLACEBO_COMPARATOR","Participants will be assigned to one of the planned dose cohorts and receive specified dose of HRS-5765 placebo.",[19],"Drug: HRS-5765 Tablet Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","HRS-5765 Tablet","HRS-5765 tablet, specified dose on specified day.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"HRS-5765 Tablet Placebo","HRS-5765 tablet placebo, specified dose on specified day.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Hui Xu","CONTACT","+86 0518-82342973","hui.xu.hx107@hengrui.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Chang Shu","+86-0518-82342973","chang.shu@hengrui.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Beijing Anzhen Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":51,"coordinates":52},"Point",[53,54],116.39723,39.9075,{"lat":54,"lon":53},[57,61,65,67],{"name":58,"role":34,"phone":59,"phoneExt":26,"email":60},"Yang Lin","+86-010-64456045","linyang@anzhengcp.com",{"name":62,"role":34,"phone":63,"phoneExt":26,"email":64},"Shan Jing","+86-010-64456014","jingshan@anzhengcp.com",{"name":58,"role":66,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"name":62,"role":66,"phone":26,"phoneExt":26,"email":26},{"type":69,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100635321","phase-1-a-clinical-study-of-hrs-5765-in-healthy-participants-100635321",false,"NCT07551167","A Clinical Study of HRS-5765 in Healthy Participants","A Randomized, Double-Blind, Dose-Escalation, Placebo-Parallel Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HRS-5765 in Healthy Subjects, as Well as the Effect of Food on the Pharmacokinetics of HRS-5765 and the Effect of HRS-5765 on CYP3A4 Metabolic Enzymes","Inclusion Criteria:\n\n1. Healthy men and women aged 18 to 65 years old at informed consent signing.\n2. Male body weight ≥ 50 kg and \\\u003C 90.0 kg, female ≥ 45 kg and \\\u003C 90.0 kg; BMI 19 to 26 kg\u002Fm² at screening and baseline.\n3. Have no clinically significant abnormalities at screening and baseline.\n4. Fertile females and males with fertile female partners: effective contraception consent, and sustained until 1 week after the last dose (abstinence or highly effective contraception); no sperm\u002Fegg donation.\n\nExclusion Criteria:\n\n1. A history or current severe diseases of multiple systems, or other diseases interfering with trial results.\n2. Severe infection, trauma, major surgery within 3 months before screening; Planned surgery during the trial.\n3. Blood donation\u002Fsevere blood loss (≥ 400 mL) within 3 months, blood transfusion within 4 weeks before screening; Planned blood donation during the trial.\n4. History of drug abuse\u002Fdependence; positive urine drug test at screening. Participation in other clinical trials within 3 months before screening or planned.\n5. Participation during the trial; Within 5 half-lives of a prior drug (whichever is longer).\n6. Smoking history (≥ 5 cigarettes\u002Fday) within 4 weeks before screening; Inability to abstain from tobacco during the trial.\n7. Positive for HBsAg, HIV antibody, Treponema pallidum antibody or HCV antibody at screening.\n8. Special dietary requirements and inability to comply with the unified diet.\n9. Difficulty in swallowing\u002Fvenous blood collection; Intolerance to intensive blood sampling.\n10. Other circumstances deemed unsuitable for trial participation by researcher.",true,"ALL","18 Years","65 Years",{"count":82,"type":83},74,"ESTIMATED","INTERVENTIONAL",[86],"PHASE1","The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.",[89],"Heart Failure","2026-05-21",{"date":92,"type":93},"2026-05-26","ACTUAL",{"date":95,"type":93},"2026-05-20",{"date":97,"type":83},"2027-01",{"name":5,"class":6},1]